302 related articles for article (PubMed ID: 20231078)
1. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Herchenhorn D; Dias FL; Viegas CM; Federico MH; Araújo CM; Small I; Bezerra M; Fontão K; Knust RE; Ferreira CG; Martins RG
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):696-702. PubMed ID: 20421154
[TBL] [Abstract][Full Text] [Related]
4. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
[TBL] [Abstract][Full Text] [Related]
5. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Kao J; Genden EM; Chen CT; Rivera M; Tong CC; Misiukiewicz K; Gupta V; Gurudutt V; Teng M; Packer SH
Cancer; 2011 Jul; 117(14):3173-81. PubMed ID: 21246519
[TBL] [Abstract][Full Text] [Related]
8. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
10. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.
Unger KR; Lominska CE; Deeken JF; Davidson BJ; Newkirk KA; Gagnon GJ; Hwang J; Slack RS; Noone AM; Harter KW
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1411-9. PubMed ID: 20056341
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
12. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
[TBL] [Abstract][Full Text] [Related]
15. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
17. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
[TBL] [Abstract][Full Text] [Related]
19. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
